Phase 2 Trial of Ixazomib in Patients With Relapsed Multiple Myeloma Not Refractory to Bortezomib

Blood Cancer Journal - United States
doi 10.1038/bcj.2015.60
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Phase I/Ii Trial of Bendamustine, Ixazomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2019English

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Retreatment With Bendamustine-Bortezomib-Dexamethasone in a Patient With Relapsed/Refractory Multiple Myeloma

Case Reports in Hematology
2016English

Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin With Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

Cancer
Cancer ResearchOncology
2016English

Phase II Trial to Investigate Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib

British Journal of Haematology
Hematology
2018English

Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma

Cancer
Cancer ResearchOncology
2010English

Ixazomib in the Treatment of Relapsed Multiple Myeloma

Medical Council
2018English

Bendamustine in Patients With Relapsed or Refractory Multiple Myeloma

European Journal of Medical Research
Medicine
2010English

Pcn104 - Economic Analysis of Costs and Resource Consumption of Ixazomib in Patients With Relapsed / Refractory Multiple Myeloma in Austria

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy